ISPOR ANNOUNCES 2016-2017 BOARD OF DIRECTORS

Published Jul 5, 2016
Princeton, NJ—July 5, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced the election of the Society’s 2016-2017 Board of Directors that assumed office on July 1, 2016. ISPOR’s Board of Directors are elected by its global membership. Lou Garrison, PhD assumes the role of President for 2016-17 after most recently serving as the Society’s President-Elect. Dr. Garrison is Professor, Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington in Seattle, WA, USA. Shelby D. Reed, RPh, PhD was elected to serve as President-Elect for the Society for 2016-17. Dr. Reed is Professor, Duke University in Durham, NC, USA. The following were elected as ISPOR Board Members for 2016-18: - Joanna Lis, MSc, MBA, PhD, Director of Market Access, Sanofi-Aventis (Warsaw, Poland) - Gordon Liu, PhD, PKU Yangtze River Scholar Professor of Economics, Peking University National School of Development, Director, PKU China Center for Health Economic Research (Beijing, China) - Rosanna Tarricone, MSc, PhD, Associate Professor, Bocconi University (Milan, Italy) - John Watkins, MPH, PharmD, Formulary Manager, Premera Blue Cross (Mountlake Terrace, WA, USA) Returning Board members include: Past President: - Daniel C. Malone, RPh, PhD, Professor of Pharmacy, College of Pharmacy and Associate Professor in Mel and Enid Zuckerman College, University of Arizona (Tucson, AZ, USA)  Treasurer: - Zeba M. Khan, RPh, PhD, Vice President, Celgene Corporation (Summit, NJ, USA) CEO and Executive Director: - Nancy S. Berg, CEO and Executive Director, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (Lawrenceville, NJ, USA) Directors: - Nancy Devlin, PhD, Director of Research, Office of Health Economics (London, UK) - Manuel Espinoza, MD, MSc, PhD, Professor, Department of Public Health and Chief, HTA Unit, Catholic University of Chile (Santiago, Chile) and Honorary Visiting Fellow, Centre for Health Economics University of York (York, UK) - Dana Goldman, PhD, Leonard D. Schaeffer Director's Chair and Director, Schaeffer Center for Health Policy and Economics, University of Southern California (Los Angeles, CA, USA)

###

Related Stories

Landmark Analysis in Value in Health Uncovers Potential Research Efficiency Gains

Sep 15, 2025

Value in Health, the official journal of ISPOR announced the publication of a landmark scoping review that provides a comprehensive mapping of patient preference studies across key medical domains, revealing the first robust evidence base for advancing meta-analyses and benefit transfer methods in healthcare decision-making.

ISPOR Real-World Evidence Summit 28-30 September 2025 | Tokyo, Japan

Sep 9, 2025

ISPOR announced details for its ISPOR Real-World Evidence Summit 2025: Through The Lens of Asia Pacific. The Summit brings together top experts, decision makers, and industry leaders to explore the latest breakthroughs, share cutting-edge research, and discuss innovative solutions to the region’s most pressing healthcare challenges.

"Most-Favored Nation" Drug Pricing Strategy May Backfire, New Research Warns

Sep 3, 2025

Value in Health, the official journal of ISPOR announced the publication of a new analysis suggesting that the Trump Administration's "Most-Favored Nation" approach to lowering US drug prices by referencing international prices may not achieve its intended goals, based on decades of experience with similar policies in Europe.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×